TAYSHA GENE THERAPIES INC (TSHA)

Company Profile

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 65 full-time employees. The company went IPO on 2020-09-24. The firm is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders, and genetic epilepsies. Its product candidates include TSHA-120, a clinical-stage, intrathecally dosed AAV9 gene therapy program for the treatment of giant axonal neuropathy (GAN); TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy product candidate in clinical evaluation for Rett syndrome; TSHA-118, a self-complementary AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 (CLN1) complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and others.

Company Info

TAYSHA GENE THERAPIES INC

3000 Pegasus Park Drive, Suite 1430

Dallas TEXAS 75247

P: 12146120000

CEO: RA Session

Employees: 65

Website: https://tayshagtx.com/